Tag Archives: biotech stocks

Advaxis Inc. ADXS

Advaxis Inc – ADXS

Advaxis Inc. is a biotechnology company having developments in immunotherapies with at aim at enlisting the immunity of the body to fight against cancer. The market cap of the company is $88.04 M and the 52-week low-high price is $1.51- $8.36. This American company has headquarters in Princeton, NJ, United States. It is devoted to the usage of Listeria monocytogenes (Lm) for innovation, progression, and marketing of immunotherapies for cancer treatment.

The platform on which the company manufactures its products is attenuated LM having an ability to secrete adjuvant fusion/antigen proteins to make an impact on the immune system of the patients. It focuses mainly on the T- cells with an immune response to the secreted antigen on the cancer cells that helps in eliminating cancer. These treatments are termed as Lm-LLO immunotherapies. At present, Advaxis has 15+ constructs in various developmental stages that are found with the direct development of the company with its excellence centers located in the different parts of the US.

Advaxis was acquired by Shell Corporation in November 2004. Great Expectations was the acquiring company at that time and it was incorporated in the year 1987. In the year 2014, Advaxis entered a commercial agreement and co-development association with Indian Biocon for the treatment of mainly HPV-associated cancers, inclusive of cervical cancer. The novel technology of Listeria monocytogenes (Lm) is bio-engineered by the experts to secrete the fusion protein. The key elements of the immune system affected by cancer are targeted and the cancer defense is handled up to 80% with this process.

The management team of Advaxis Inc. is highly capable having skilled personnel with the proven track record in the medical and commercial industry for cancer therapies. The research team is dedicated and committed to the new approach and development in the cancer care industry. There are most rewarding collaborations made with the major Pharma companies to enhance the market trust and save lives of millions of people suffering from cancer. The company has all its treatments approved by FDA and has a promising treatment option which is the major reason for the stockers to trust them to make secured investments.

Lm technology immunotherapies have the best anti-tumor response with the costimulatory molecules and checkpoint inhibitors. The strategic collaborations of the company with other Pharma companies for development and commercialization of the products is a great step in establishing a positive impact on the medical world. The immunotherapies development is in partnership with the esteemed cancer centers and has a full support of the advocacy foundations.

The strong management of the company is led by the President and CEO Mr. Kenneth A. Berlin. He has been heading this post for last 9+ years and has led to the successfully led the projects for developments in the cancer industry. The team and management are extensively knowledgeable in their streams and have a successful track record in development and commercialization of anti-cancer drugs. The company has a positive future with the listed policies and every associated member is trying to make it as a successful move to pursue the cancer immunotherapy treatment.

Share This:

Read More

Biostem U.S. Corp. HAIR

I’m on fire about Biostem U.S. Corp. (HAIR) today and the reason is in the ticker itself.

HAIR uses ethically harvested adult stem cells to super-charge balding scalps.

They say it’s virtually painless and you can do it on your lunch break.

You can imagine how much cash an outpatient cure for baldness would pull in!

And yet somehow HAIR is currently priced in the 20 cent range, so everyman traders like us still have a chance to see it on the ground floor.

See, HAIR is only now rolling its stem cell technique into hair transplant clinics in places like Orlando, Florida, where aging big shots want to stay young-looking forever.

HAIR will receive monthly revenue from each doctor who signs up.

Because they’re starting from near-zero here, every dollar moves the valuation needle.

And those first clinics just opened for stem cells a few weeks ago, so the inflection point here is as fresh as it gets!

Now that the wheels have finally started turning, HAIR could even become an attractive Big Biotech merger target.

After all, Propecia brings down $400 million a year for Merck.

And old Rogaine earned its maker $150 million a year back in the 90s.

The market is endless. Look for baldness cure online, 3 MILLION hits.

Just a few months ago, news that they’d found the cause of baldness drove the world wild.

A cure in five years? HAIR is already doing it!

HAIR is also turning heads as brokerage firms throw it cash for the privilege of getting their taste of this story before the Street catches on.

Elco Securities bought 20 million HAIR shares back in May at 25 cents apiece.

That’s a 65% premium over where HAIR was trading the day the deal was signed.

Remember, HAIR is now well under the $0.25 level so that position is still technically deep underwater.

Did the big boys at Elco get taken here or did they figure that $5 MILLION bet will be worth a lot more down the road?

All I know is that HAIR plans to use that cash to keep the lights on while its marketing team goes to work!

This board is stacked with top management from blue-chip corporations like Crocs.

Love or hate the shoes, Stephen Beck and Scott Crutchfield know how to build a multi-billion-dollar craze from the ground up, and they seem eager to do it again.

Bottom Line: HAIR just blasted out of the gate with a new revenue model and some of the biggest names in hair replacement on its team.

Smart players have gambled long green on this company and its technology.


Share This:

Read More

Penny Stocks NNVC, NanoViricides, Inc. UNSS, Universal Solar Technology Inc.

UNSS, Universal Solar Technology Inc. and NNVC, NanoViricides, Inc., NNVC.OB

NNVC is a development stage company that is creating special purpose nanomaterials for viral therapy. NNVC’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

NNVC is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Dengue is receiving significant international attention as it threatens over 40% of the world population, according to The World Health Organization (WHO).

Dengue cases with significant fatality rates have started rising in tropical countries this year already, as demonstrated by reports from India, Sri Lanka, Indonesia, Philippines, Cambodia, and Colombia, among others.

Dengue is endemic in Asia, Mexico, the Caribbean, Central America and many countries in South America. Dengue virus infections have occurred in the southern US states, including a current outbreak in Key West, and travel leads to sporadic cases of dengue in the US.

Dengue virus, a member of the Flaviviridae family of viruses that includes West Nile and Hepatitis C viruses, is transmitted to humans via female Aedes mosquitoes.

There are 4 different serotypes of Dengue virus that infect humans.

When a person is infected with Dengue virus for the first time, the disease may not be severe, inducing fever, muscle and joint pain, and rash. When the same person is later infected by a different Dengue virus serotype a more severe disease may develop; Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) occurs in a significant portion of this population. This DHF/DSS may be due to ADE caused by antibodies produced during the first infection. According to the WHO, fatality rates of DHF/DSS can exceed 20%.

Currently there are no approved vaccines for prevention nor drugs for treatment of Dengue virus infection.

Check this out:

NNVC’s anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley).

Treatment with one of the anti-Dengue NNVC’s nanoviricides led to survival of 50% of the animals for the duration of study in the ADE model. In addition, animals treated with several anti-Dengue nanoviricides survived longer than the control animals treated with vehicle alone. This ADE model of infection is uniformly fatal in 100% of the infected animals within 5 days after infection.

Keep a close eye on NNVC from now on!

More about NNVC atwww.nanoviricides.com


UNSS, Universal Solar Technology Inc., UNSS.OB

UNSS manufacturers solar products and provides solar power systems using advanced manufacturing technologies and equipments.

UNSS‘ products include solar-grade silicon material (ingots and wafers), solar modules, solar lights and solar power systems.

Arizona State University Photovoltaic Testing Laboratory has certified that UNSS Photovoltaic Modules satisfy the standards and requirements of the International Engineering Consortium and has passed the standards for selling products to countries in the European Union.

** UNSS reported the signing of a sales contract for $32,600,000 with CEZ Group, part of the largest electricity producer in the Czech Republic. The contract calls for the delivery of 20MW of monocrystaline solar modules to be delivered by the end of 2010.

The strategic goal of CEZ Group is to become the leader on the Central and Southeastern European electricity market. Apart from the production and sale of electricity, CEZ Group also deals in telecommunications, informatics, nuclear research, planning, construction and maintenance of energy facilities, mining raw materials, and processing energy by-products.

CEZ Group currently belongs among the three largest heat suppliers in the CzechRepublic.

Be sure UNSS is on your watch list!

UNSS could be at the beginning of a rally and you don’t want to be out of the action!

More about UNSS atwww.ustnevada.com/en


NNVC and UNSS are on PennyOmega.com’s RADAR! Do your homework, and like always BE READY for the Action!!!




Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. awesomepennystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold awesomepennystocks.com report  its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.

Share This:

Read More

List of Biotech Stocks to watch

Biotech Stocks

What are Biotech Stocks?

Biotechnology is one the weirdest, scariest, sexiest and most intriguing corners of the stock market. The Organizations can actually help save lives! Any industry can have a stock that could conceivably twofold, yet what other industry can coordinate biotechnology in the sheer number of stocks that could twofold if their organizations’ arranges all worked out as intended?

What Is Biotechnology?

More or less, biotechnology is an industry that spotlights on novel medication advancement and clinical exploration went for treating infections and therapeutic conditions. Biotechnology organizations are quite often unrewarding (some recommend that the refinement amongst “biotech” and “pharmaceutical organization” lies in benefit), and numerous have no genuine income by any stretch of the imagination.

Biotechnology is likewise described by long improvement lead times; it can take as much as 10 years to get another medication from test tube to drugstore rack. Besides, is a mind-boggling probability of disappointment, as 85-95% of all imminent new medications neglect to achieve endorsement. Still, for those that succeed, the prizes can be colossal and “everyday pairs” are not unbelievable.

Be careful the Gatekeeper

As the administrative body that affirms new medications for the U.S. market, and in addition allowing human clinical trials, the Food and Drug Administration (FDA) is a definitive watchman to each biotech’s prosperity. The FDA requires that all organizations build up (agreeable to its) that a potential new medication is sheltered and solid for its expressed reason.

Financial specialists need to comprehend the FDA procedure and necessities. With a specific end goal to get FDA endorsement, biotechs must build up an adequate assortment of data that the medication is protected and powerful and this is for the most part done through a progression of no less than three clinical trials (Phase One, Phase Two and Phase Three).

What Biotech Investors Need to Know

While considering a potential biotechnology venture, there are a few extra calculates to keep mind:

1. Pipeline

A biotech’s pipeline is everything, and it is the wellspring of the organization’s assumed and anticipated worth. As a rule, financial specialists ought to attempt to center their consideration on organizations with different Phase 2 programs. Doubtlessly single-item biotechs can be huge champs when they succeed, however, the converse is additionally genuine – they can endure pounding misfortunes if that unparalleled item applicant falls flat.

2. Not all illnesses are similarly important

A few illnesses are colossal potential markets, however, have sufficient rivalry and strict desires for security or execution. Case in point, while tumor and cancer are real maladies with multibillion-dollar potential, there are various medications effectively affirmed and accessible – if new medications don’t offer something novel (better viability, fewer reactions, and so on.), they may not, in any case, get endorsed, not to mention locate a huge business sector.

3. Corporate reasoning

Financial specialists likewise need to comprehend the targets and objectives of organization administration. Numerous biotechs mean to build up their medications just so far all alone and afterward fundamentally exchange them to a bigger medication organization in return for forthright money and future eminences. Different organizations, however, hush up about the promoting rights and work out their own business power. Eventually, these appear to be the organizations that assemble the most esteem for shareholders, yet it’s a less secure way.

Share This:

Read More